12 kb sequence immediately adjacent to and upstream of the AKT1 gene locus containing multiple genetic variations associated with changes in metabolic syndrome, and methods of use

Abstract

We have identified a 12 kb sequence immediately upstream of the AKT1 gene locus in humans that contains single nucleotide polymorphic polynucleotide (SNPs) whose alleles in strong linkage disequilibrium, and that are prognostic for metabolic syndrome and its metabolic sequellae such as hyperglycemia and type 2 diabetes. The +G205T allele is particularly highly predictive of the potential for protection against metabolic syndrome and its sequellae. The detection of these SNPs by the techniques described herein forms the foundation for methods for genotype-specific clinical interventions designed to slow the rapid population increases in metabolic syndrome and its metabolic sequellae.

Description

Claims

1. A composition, comprising a single polymorphic polynucleotide (SNP) located in the 12 kb DNA sequence immediately upstream of the AKT1 gene locus in humans, said 12 kb sequence including the first exon and upstream regulatory regions, and said SNP being a member of a haplotype whose alleles are in linkage disequilibrium, wherein said SNP is associated with protection against metabolic syndrome and its metabolic sequellae.

2. The composition of claim 1 wherein said SNP is selected from the haplotype group consisting of SEQ ID Nos. 1 through 4, or a complementary strand of SEQ ID Nos. 1 through 4

3. The composition according to claim 2, wherein said SNP has the sequence shown in SEQ ID No. 1, and said allele is +G205T.

4. The composition according to claim 2, wherein said SNP has the sequence shown in SEQ ID No. 2 and said allele is +G233A.

5. The composition according to claim 2, wherein said SNP has the sequence shown in SEQ ID No. 3, and said allele is −C8,166T

6. The composition according to claim 2, wherein said SNP has the sequence shown in SEQ ID No. 4, and said allele is −C11,898A.

7. A method for predicting presymptomatically the likelihood that a human will have a genetic propensity for metabolic syndrome and its metabolic sequellae, comprising the steps of obtaining a tissue sample from said human, isolating genomic DNA from said tissue sample, assaying said genomic DNA for the presence or absence of the SNP of claim 1, wherein the presence of said SNP in said DNA sample predicts protection against said metabolic syndrome and its metabolic sequellae.

8. The method according to claim 7, wherein said SNP has the sequence of SEQ ID No. 1, and said allele is +G205T.

9. The method according to claim 7, wherein said SNP has the sequence of SEQ ID No 2, and said allele is +G233A.

10. The method according to claim 7, wherein said SNP has the sequence of SEQ ID No. 3, and said allele is −C8,166T.

11. The method according to claim 7, wherein said SNP has the sequence of SEQ ID No. 4, and said allele is −C11,898A.

12. A method of clinical intervention against metabolic syndrome and its metabolic sequellae in a human, comprising the steps of (i) assaying for the presence or absence of the SNP of claim 1 in the genomic DNA of said human; and (ii) administering a clinical regimen, where needed, appropriate to the presence or absence of a protective allele in said human and the potential for the onset of the metabolic syndrome and its metabolic sequellae.

13. The method according to claim 12, wherein said SNP has the sequence of SEQ ID No. 1, and said allele is +G205T.

14. The method according to claim 12, wherein said SNP has the sequence of SEQ ID No. 2, and said allele is −G233A.

15. The method according to claim 12 wherein said SNP has the sequence of SEQ ID No. 3, and said allele is −C8,166T.

16. The method according to claim 12, wherein said SNP has the sequence of SEQ ID No. 4, and said allele is −C11,898A.